-
公开(公告)号：US20190192549A1
公开(公告)日：2019-06-27
申请号：US16185258
申请日：2018-11-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： MASATO YOSHIKAWA , Morihisa Saitoh , Taisuke Kato , Yayoi Yoshitomi , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , A61K47/68 , A61K31/7076
CPC classification number: A61K31/7084 , A61K31/7076 , A61K47/6807 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
-
公开(公告)号：US11542293B2
公开(公告)日：2023-01-03
申请号：US16762710
申请日：2018-11-09
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Stepan Vyskocil , Jeffrey Ciavarri , Courtney Cullis , Dylan Bradley England , Alexandra E. Gould , Paul Greenspan , Yongbo Hu , Steven Langston , Gang Li , Hirotake Mizutani , Masanori Okaniwa
IPC: C07H19/207
Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US12054512B2
公开(公告)日：2024-08-06
申请号：US18052083
申请日：2022-11-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Stepan Vyskocil , Jeffrey Ciavarri , Courtney Cullis , Dylan Bradley England , Alexandra E. Gould , Paul Greenspan , Yongbo Hu , Steven Langston , Gang Li , Hirotake Mizutani , Masanori Okaniwa
IPC: C07H19/207
CPC classification number: C07H19/207
Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases.
The present disclosure relates to a compound represented by the Formula (I):
wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20210106607A1
公开(公告)日：2021-04-15
申请号：US17065242
申请日：2020-10-07
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： MASATO YOSHIKAWA , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , C07H21/00 , C07H21/02 , A61K47/68 , A61K31/7076
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US20170037057A1
公开(公告)日：2017-02-09
申请号：US15304727
申请日：2015-04-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masanori Okaniwa , Hiroshi BANNO , Takaharu HIRAYAMA , Douglas Robert CARY , Koji ONO , Naoki IWAMURA
IPC: C07D513/04
CPC classification number: C07D513/04 , A61K31/429 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/455 , A61K31/5377
Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.
Abstract translation: （其中符号如说明书中所定义）或其盐。
-
Patent Agency Ranking
公开(公告)号：US10800754B2
公开(公告)日：2020-10-13
申请号：US16332993
申请日：2017-09-14
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Masato Yoshida , Shinichi Imamura
IPC: C07D401/04 , C07D401/14 , C07D407/14 , C07D409/14 , C07D417/14 , A61P35/00
Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US09745325B2
公开(公告)日：2017-08-29
申请号：US15304727
申请日：2015-04-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masanori Okaniwa , Hiroshi Banno , Takaharu Hirayama , Douglas Robert Cary , Koji Ono , Naoki Iwamura
IPC: C07D513/04 , A61K31/429 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/455 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/429 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/455 , A61K31/5377
Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.
-
公开(公告)号：US12171777B2
公开(公告)日：2024-12-24
申请号：US18310467
申请日：2023-05-01
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61K31/7076 , A61K47/68 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US11666594B2
公开(公告)日：2023-06-06
申请号：US17065242
申请日：2020-10-07
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , C07H21/00 , C07H21/02 , A61K47/68 , A61K31/7076
CPC classification number: A61K31/7084 , A61K31/7076 , A61K47/6807 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US10774083B2
公开(公告)日：2020-09-15
申请号：US16333296
申请日：2017-09-14
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Shinichi Imamura
IPC: C07D401/04 , C07D401/14 , C07D473/28 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/40 , C07D519/00 , A61P35/00 , A61K31/506 , A61K31/444 , A61K31/4439 , C07D473/00 , C07D473/32 , A61K31/5377 , A61K31/501 , A61K31/52 , A61P43/00 , A61K31/437 , C12N9/99
Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.034 seconds)
